429 related articles for article (PubMed ID: 23856380)
1. Association of a change in erythropoiesis-stimulating agent dose during hospitalization and subsequent hemoglobin levels and transfusions in hemodialysis patients.
Wong BC; Ravani P; Manns BJ; Lewin A; Zhang X; Chin R; Hemmelgarn BR; Tonelli M; Oliver MJ; Quinn RR
Am J Kidney Dis; 2013 Nov; 62(5):947-52. PubMed ID: 23856380
[TBL] [Abstract][Full Text] [Related]
2. Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients.
Nishio A; Chhatkuli BP; Ma JZ; Kalantari K
Blood Purif; 2013; 36(1):29-36. PubMed ID: 23735569
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
Solomon SD; Uno H; Lewis EF; Eckardt KU; Lin J; Burdmann EA; de Zeeuw D; Ivanovich P; Levey AS; Parfrey P; Remuzzi G; Singh AK; Toto R; Huang F; Rossert J; McMurray JJ; Pfeffer MA;
N Engl J Med; 2010 Sep; 363(12):1146-55. PubMed ID: 20843249
[TBL] [Abstract][Full Text] [Related]
4. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
5. RBC transfusions among hemodialysis patients (1999-2010): influence of hemoglobin concentrations below 10 g/dL.
Gilbertson DT; Monda KL; Bradbury BD; Collins AJ
Am J Kidney Dis; 2013 Nov; 62(5):919-28. PubMed ID: 23815986
[TBL] [Abstract][Full Text] [Related]
6. Treatment with high dose of erythropoiesis-stimulating agents and mortality: analysis with a sequential Cox approach and a marginal structural model.
Suttorp MM; Hoekstra T; Mittelman M; Ott I; Krediet RT; Dekker FW; Putter H
Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1068-75. PubMed ID: 26265483
[TBL] [Abstract][Full Text] [Related]
7. Biomedical system dynamics to improve anemia control with darbepoetin alfa in long-term hemodialysis patients.
McCarthy JT; Hocum CL; Albright RC; Rogers J; Gallaher EJ; Steensma DP; Gudgell SF; Bergstralh EJ; Dillon JC; Hickson LJ; Williams AW; Dingli D
Mayo Clin Proc; 2014 Jan; 89(1):87-94. PubMed ID: 24388026
[TBL] [Abstract][Full Text] [Related]
8. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
Regidor DL; Kopple JD; Kovesdy CP; Kilpatrick RD; McAllister CJ; Aronovitz J; Greenland S; Kalantar-Zadeh K
J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
[TBL] [Abstract][Full Text] [Related]
9. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
[TBL] [Abstract][Full Text] [Related]
10. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
[TBL] [Abstract][Full Text] [Related]
11. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
[TBL] [Abstract][Full Text] [Related]
12. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy.
Foley RN; Curtis BM; Parfrey PS
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1669-75. PubMed ID: 18922988
[TBL] [Abstract][Full Text] [Related]
13. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan.
Fukuma S; Yamaguchi T; Hashimoto S; Nakai S; Iseki K; Tsubakihara Y; Fukuhara S
Am J Kidney Dis; 2012 Jan; 59(1):108-16. PubMed ID: 21890255
[TBL] [Abstract][Full Text] [Related]
14. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis.
Macdougall IC; Provenzano R; Sharma A; Spinowitz BS; Schmidt RJ; Pergola PE; Zabaneh RI; Tong-Starksen S; Mayo MR; Tang H; Polu KR; Duliege AM; Fishbane S;
N Engl J Med; 2013 Jan; 368(4):320-32. PubMed ID: 23343062
[TBL] [Abstract][Full Text] [Related]
15. Peginesatide in patients with anemia undergoing hemodialysis.
Fishbane S; Schiller B; Locatelli F; Covic AC; Provenzano R; Wiecek A; Levin NW; Kaplan M; Macdougall IC; Francisco C; Mayo MR; Polu KR; Duliege AM; Besarab A;
N Engl J Med; 2013 Jan; 368(4):307-19. PubMed ID: 23343061
[TBL] [Abstract][Full Text] [Related]
16. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
[TBL] [Abstract][Full Text] [Related]
17. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.
Koulouridis I; Alfayez M; Trikalinos TA; Balk EM; Jaber BL
Am J Kidney Dis; 2013 Jan; 61(1):44-56. PubMed ID: 22921639
[TBL] [Abstract][Full Text] [Related]
18. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients.
Weinhandl ED; Gilbertson DT; Collins AJ
Am J Nephrol; 2011; 34(4):298-308. PubMed ID: 21829009
[TBL] [Abstract][Full Text] [Related]
19. Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients.
Sibbel SP; Koro CE; Brunelli SM; Cobitz AR
BMC Nephrol; 2015 Aug; 16():144. PubMed ID: 26283069
[TBL] [Abstract][Full Text] [Related]
20. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]